A recent molecular study of myxoid uterine leiomyosarcomas (M-LMS) reported that almost 1/3 of cases harbor PLAG1 fusions. A single additional report described M-LMS with PLAG1 fusion and osteosarcomatous and liposarcomatous (LPS) differentiation.
Triggered by a case of PLAG1-rearranged uterine sarcoma (PLAG1-US) lacking convincing expression of smooth muscle markers (SMM), we decided to study a larger cohort of these tumors.